Chronic migraine with daily headache. Literature review

被引:2
作者
Martinez-Pias, Enrique [1 ]
Garcia-Azorin, David [1 ]
Trigo-Lopez, Javier [1 ]
Sierra, Alvaro [1 ]
Guerrero-Peral, Angel L. [1 ,2 ,3 ]
机构
[1] Hosp Clin Univ Valladolid, Unidad Cefaleas, Serv Neurol, Avda Ramon y Cajal 3, E-47005 Valladolid, Spain
[2] Univ Valladolid, Dept Med, Valladolid, Spain
[3] Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain
关键词
Botulinum toxins type A; Chronic daily headache; Chronic migraine; Daily headache; Headache; Treatment; MEDICATION OVERUSE HEADACHE; NEAR-DAILY HEADACHES; DOUBLE-BLIND; CLINICAL CHARACTERISTICS; PREVENTIVE TREATMENT; EPISODIC MIGRAINE; PREVALENCE; POPULATION; EPIDEMIOLOGY; CLASSIFICATION;
D O I
10.33588/rn.7204.2020583
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Despite representing a significant number of cases, patients with chronic migraine and daily headache are frequently excluded from large therapeutic clinical trials. These individuals have hardly been studied and could have specific properties. Body. A third of patients with chronic migraine may suffer from headaches every day, representing up to 1.7 - 3.3% of patients in a general neurology consultation. These patients are excluded from most studies, so little information is available. They may have a longer lasting migraine and different response to treatment. Patients with chronic migraine and daily headache may have complex pathophysiological mechanisms that favor the daily manifestation of migraine. The management of these patients is a therapeutic challenge, and OnabotulinumtoxinA may be useful. Conclusion. Patients with chronic migraine and daily headache may have specific clinical and therapeutic characteristics. New studies could lead to differentiate it from chronic migraine.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 65 条
[1]   Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study [J].
Alpuente, Alicia ;
Gallardo, Victor Jose ;
Torres-Ferrus, Marta ;
Alvarez-Sabin, Jose ;
Pozo-Rosich, Patricia .
HEADACHE, 2020, 60 (04) :677-685
[2]   Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study [J].
Bigal, Marcelo E. ;
Serrano, Daniel ;
Buse, Dawn ;
Scher, Ann ;
Stewart, Walter F. ;
Lipton, Richard B. .
HEADACHE, 2008, 48 (08) :1157-1168
[3]   Assessment of migraine disability using the Migraine Disability Assessment (MIDAS) Questionnaire: A comparison of chronic migraine with episodic migraine [J].
Bigal, ME ;
Rapoport, AM ;
Lipton, RB ;
Tepper, SJ ;
Sheftell, FD .
HEADACHE, 2003, 43 (04) :336-342
[4]   Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS) [J].
Blumenfeld, A. M. ;
Varon, S. F. ;
Wilcox, T. K. ;
Buse, D. C. ;
Kawata, A. K. ;
Manack, A. ;
Goadsby, P. J. ;
Lipton, R. B. .
CEPHALALGIA, 2011, 31 (03) :301-315
[5]   OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse [J].
Caronna, Edoardo ;
Jose Gallardo, Victor ;
Hernandez-Beltran, Natalia ;
Torres-Ferrus, Marta ;
Pozo-Rosich, Patricia .
FRONTIERS IN NEUROLOGY, 2018, 9
[6]  
Castillo J, 1999, Headache, V39, P190
[7]   Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine [J].
Cernuda-Morollon, Eva ;
Larrosa, Davinia ;
Ramon, Cesar ;
Vega, Juan ;
Martinez-Camblor, Pablo ;
Pascual, Julio .
NEUROLOGY, 2013, 81 (14) :1191-1196
[8]   Chronic Daily Headache and Medication Overuse Headache in First-Visit Headache Patients in Korea: A Multicenter Clinic-Based Study [J].
Cha, Myoung-Jin ;
Moon, Heui-Soo ;
Sohn, Jong-Hee ;
Kim, Byung-Su ;
Song, Tae-Jin ;
Kim, Jae-Moon ;
Park, Jeong Wook ;
Park, Kwang-Yeol ;
Kim, Soo-Kyoung ;
Kim, Byung-Kun ;
Cho, Soo-Jin .
JOURNAL OF CLINICAL NEUROLOGY, 2016, 12 (03) :316-322
[9]   Headache Frontiers: Using Magnetoencephalography to Investigate Pathophysiology of Chronic Migraine [J].
Chen, Wei-Ta ;
Lin, Yung-Yang ;
Wang, Shuu-Jiun .
CURRENT PAIN AND HEADACHE REPORTS, 2013, 17 (01)
[10]   Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study [J].
Detke, Holland C. ;
Goadsby, Peter J. ;
Wang, Shufang ;
Friedman, Deborah I. ;
Selzler, Katherine J. ;
Aurora, Sheena K. .
NEUROLOGY, 2018, 91 (24) :E2211-E2221